Malay B. Shah, MD, FACS
Surgical Director, Liver Transplant Program
- Hepatobiliary/Pancreatic Cancer Team
- Liver Cancer Team
- Pancreas Cancer Team
- Pediatric Kidney Transplant Team
- Transplant Surgery
- Transplant: Hepatobiliary
- Transplant: Kidney
- Transplant: Kidney/Pancreas
- Transplant: Liver
- Transplant: Pancreas
Assistant Professor of Surgery
- Clinical Outcomes
- Hepatobiliary Surgery
- Hepatocellular Carcinoma (HCC)
- Liver, Kidney and Pancreas Transplantation
- Vascular Access
The University of Toledo, College of Medicine, Toledo, Ohio
Medical College of Georgia, Augusta
Abdominal Transplant Surgery, University of Alabama at Birmingham
Certifications or Special training
American Board of Surgery
My name is Malay Shah; I am the Surgical Director of the Liver Transplant Program. I am from
the Cincinnati area and attended college at the University of Cincinnati. While in Cincinnati,
I worked closely with individuals who were involved in transplant and immunosuppression
outcomes research. At this time I developed a keen interest in transplantation. I
subsequently attended medical school in Toledo, Ohio at the Medical College of Ohio, and then
completed a general surgery residency at the Medical College of Georgia.
I completed a
transplant surgery fellowship at the University of Alabama at Birmingham. When I finished
my training, I eagerly jumped at the opportunity to come to the University of Kentucky and
return to the area I consider home.
My interests include liver, kidney and pancreas transplantation. I also have significant interests in hepatobiliary surgery, liver tumors cholangiocarcinoma and vascular access for patients with renal failure. I have a keen interest in socioeconomic and healthcare disparities and their impact on organ donation. I actively participate in national organizations such as the United Network of Organ Sharing as well as multiple transplant societies.
Crittenden NE, Buchanan LA, Pinkston CM, Cave B, Barve A, Marsano L, McClain CJ, Jones CM, Marvin MR, Davis EG, Kuns-Adkins CB, Gedaly R, Brock G, Shah MB, Rosenau J, Cave MC. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Liver Transpl. 2016 May;22(5):635-43.
Vilchez V, Turcios L, Zaytseva Y, Stewart R, Lee EY, Maynard E, Shah MB, Daily MF, Tzeng CD, Davenport D, Castellanos AL, Krohmer S, Hosein PJ, Evers BM, Gedaly R. Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma.
Am J Surg. 2016 Feb 27.
Vilchez V, Shah MB, Daily MF, Pena L, Tzeng CW, Davenport D, Hosein PJ, Gedaly R, Maynard E. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.
HPB (Oxford). 2016 Jan;18(1):29-34.
Dela Cruz AC, Vilchez V, Kim S, Barnes B, Ravinuthala A, Zanni A, Galuppo R, Sourianarayanane A, Patel T, Maynard E, Shah MB, Daily MF, Uhl T, Esser K, Gedaly R. A prospective analysis of factors associated with decreased physical activity in patients with cirrhosis undergoing transplant evaluation.
Clin Transplant. 2015 Nov;29(11):958-64.
Hance JM, Harris JW, Neltner J, Vilchez V, Tzeng CW, Maynard E, Gedaly R, Shah MB. Hepatobiliary mucinous cystadenoma resulting in biliary obstruction.
Am Surg. 2015 Jun;81(6):E238-9.